8.23

1.36% +0.14

Sana Biotechnology Inc (SANA)

Overview News Price History Option Chain Why SANA Down? Discussions Forecast

Sana Biotechnology Inc stock is currently priced at $8.23, with a 24-hour trading volume of 65,174. It has seen a +1.36% increased in the last 24 hours and a -10.38% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $8.11 pivot point. If it approaches the $8.31 resistance level, significant changes may occur.

Previous Close:

$8.09

Open:

$8.16

24h Volume:

65,174

Market Cap:

$1.78B

Revenue:

Net Income/Loss:

$-283.26M

P/E Ratio:

-4.3545

EPS:

-1.89

Net Cash Flow:

$-273.61M

1W Performance:

-0.73%

1M Performance:

-10.38%

6M Performance:

+175.17%

1Y Performance:

+63.02%

1D Range:

$8.04

$8.33

52W Range:

$2.745

$12.00

Sana Biotechnology Inc Stock (SANA) Company Profile

Name

Sana Biotechnology Inc

Sector

Healthcare (1203)

Industry

Biotechnology (685)

Phone

206 701 7914

Address

188 East Blaine Street, Suite 400, Seattle

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

SANA's Discussions on Twitter

Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-25-23	Initiated	JMP Securities	Mkt Outperform
Sep-05-23	Initiated	Citigroup	Buy
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	BofA Securities	Buy
Mar-01-21	Initiated	Goldman	Neutral
Mar-01-21	Initiated	JP Morgan	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight

View All

Sana Biotechnology Inc Stock (SANA) Latest News

Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday

Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire Inc.

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

GlobeNewswire Inc.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

GlobeNewswire Inc.

Sana Biotechnology Inc Stock (SANA) Financials Data

Sana Biotechnology Inc (SANA) Net Income 2024

SANA net income (TTM) was -$283.25 million for the quarter ending December 31, 2023, a -5.11% decrease year-over-year.

Sana Biotechnology Inc (SANA) Cash Flow 2024

SANA recorded a free cash flow (TTM) of -$273.61 million for the quarter ending December 31, 2023, a +12.00% increase year-over-year.

Sana Biotechnology Inc (SANA) Earnings per Share 2024

SANA earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a -2.80% decline year-over-year.

Sana Biotechnology Inc Stock (SANA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
NELSEN ROBERT	Director	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022
ARCH Venture Fund X, L.P.	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022
CRANDELL KEITH	10% Owner	Feb 08 '24	Buy	5.50	1,818,181	9,999,996	12,446,022
Hordo Christian	EVP, Chief Business Officer	Dec 15 '23	Sale	4.00	75,000	300,098	867,455
Flagship Ventures Fund V Gener	10% Owner	Jun 07 '23	Sale	6.24	200,000	1,247,940	1,380,277
Flagship Ventures Fund V Gener	10% Owner	Jun 06 '23	Sale	6.31	203,758	1,284,918	1,403,037
Flagship Ventures Fund V Gener	10% Owner	May 26 '23	Sale	6.23	82,000	510,573	1,425,334
Flagship Ventures Fund V Gener	10% Owner	May 25 '23	Sale	6.35	115,372	732,866	1,434,664
Flagship Ventures Fund V Gener	10% Owner	May 24 '23	Sale	6.57	347,870	2,283,836	1,447,791

Sana Biotechnology, Inc. develops and delivers engineered cells as medicine for patients. It identifies and develops potential product candidates; and executes preclinical studies. The company develops technologies to repair and control genes in cells; and replace any cell in the body. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was founded in 2018 and is based in Seattle, Washington with additional offices in South San Francisco, California; and Cambridge, Massachusetts.